These results indicate that long‐term treatment with DPP‐4 inhibitors could have a significant impact on body weight control and energy homeostasis by modulating BAT activity, providing a validation of DPP‐4 inhibition as a viable therapeutic option for the treatment of metabolic disorders related to diabetes and obesity. The gene discussed is DPP4; the disease is diabetes mellitus.